Centessa Pharmaceuticals plc (CNTA)

GB — Healthcare Sector
Peers: IPSC  EWTX  CCCC  MLYS  CGEM  NAMSW  STRO  OPT  HLVX  NUVL  TARS  GNFT  GRCL  THRX  GLUE  DSGN  ERAS  CRNX  TRDA  IRON  LRMR 

Automate Your Wheel Strategy on CNTA

With Tiblio's Option Bot, you can configure your own wheel strategy including CNTA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CNTA
  • Rev/Share 0.0
  • Book/Share 2.9034
  • PB 4.6188
  • Debt/Equity 0.021
  • CurrentRatio 14.3673
  • ROIC -0.3953

 

  • MktCap 1790967159.0
  • FreeCF/Share -1.2181
  • PFCF -11.052
  • PE -7.9689
  • Debt/Assets 0.0154
  • DivYield 0
  • ROE -0.569

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation CNTA Needham -- Buy -- $35 May 28, 2025
Initiation CNTA Chardan Capital Markets -- Buy -- $30 May 8, 2025
Initiation CNTA Piper Sandler -- Overweight -- $38 March 31, 2025
Initiation CNTA TD Cowen -- Buy -- -- Jan. 7, 2025
Upgrade CNTA Morgan Stanley Equal Weight Overweight $11 $26 Sept. 20, 2024
Initiation CNTA B. Riley Securities -- Buy -- $33 Sept. 19, 2024

News

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
CNTA
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

Read More
image for news Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
CNTA
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

BOSTON and LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2024.

Read More
image for news Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

About Centessa Pharmaceuticals plc (CNTA)

  • IPO Date 2021-05-28
  • Website https://www.centessa.com
  • Industry Biotechnology
  • CEO Dr. Saurabh Saha M.D., Ph.D.
  • Employees 77
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.